Gracell Biotechnologies Inc. today announced that it will participate in the BTIG Virtual Biotechnology Conference 2021 (details below).
SUZHOU, China and PALO ALTO, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the BTIG Virtual Biotechnology Conference 2021 (details below).
BTIG Virtual Biotechnology Conference 2021
One-on-one and small group meetings: August 9-10, 2021
Fireside chat: Tuesday, August 10, 2021, 9:30 – 9:55am ET
For more information, please contact your BTIG representative.
About Gracell
Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com
Follow @GracellBio on LinkedIn
Media contact
Marvin Tang
Investor contact
Gracie Tong
